Key Highlights
- Shares of BIAF rallied more than 55% Tuesday following the company’s announcement of a new application for its CyPath Lung diagnostic test
- BioAffinity is investigating CyPath Lung as a surveillance tool for identifying cancer recurrence in patients who completed curative treatment
- More than 680,000 Americans were living with a previous lung cancer diagnosis as of the start of 2025
- Daily trading volume surpassed 17 million shares, significantly higher than the three-month average of 5.91 million
- Spark’s AI analyst assigns BIAF an Underperform rating with a $5.50 target price, pointing to cash depletion and falling revenues
Shares of BioAffinity Technologies climbed more than 55% during Tuesday’s session after the biotechnology firm issued a press release detailing plans to expand CyPath Lung’s use for monitoring lung cancer survivors.
bioAffinity Technologies, Inc., BIAF
The stock began trading at elevated levels, having jumped 65.57% during premarket hours. This came after a 6.37% decline in the previous session. Despite Tuesday’s rally, BIAF remains down 74.24% year-to-date and has plummeted 95.72% over the trailing twelve months.
The biotechnology company announced it is investigating CyPath Lung as a monitoring solution for detecting cancer recurrence in individuals who have completed curative-intent therapy.
Data from the American Cancer Society indicates that over 680,000 Americans were alive with a previous lung cancer diagnosis at the beginning of 2025. The National Cancer Institute projects approximately 230,000 new diagnoses in 2026.
When patients complete treatment, discovering a new pulmonary nodule during scans presents significant diagnostic challenges. While CT scans can identify nodules, they frequently cannot differentiate between malignant tumors, new cancerous growths, or benign post-treatment changes like scar tissue or inflammation.
CyPath Lung delivers a binary outcome: either “unlikely” or “likely” malignancy. This classification could assist healthcare providers in determining which patients require additional testing versus those who can continue with standard monitoring protocols.
Medical literature indicates recurrence rates for non-small cell lung cancer range from 20% to 55%, varying by disease stage and therapeutic approach. The American Society of Clinical Oncology suggests surveillance imaging twice yearly for the first two years following curative-intent therapy for stage I through III NSCLC.
Performance Data for CyPath Lung
The diagnostic test employs flow cytometry combined with proprietary artificial intelligence to examine cell populations within patient sputum samples. Results from a published clinical study demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and a 99% negative predictive value for identifying early-stage lung cancer in high-risk individuals.
According to BioAffinity, three years of real-world commercial deployment have demonstrated the test’s ability to help physicians evaluate malignancy risk and inform patient management, including situations where imaging findings and predictive algorithms yielded contradictory information.
Company CEO Maria Zannes stated that post-treatment surveillance “has the potential to lead to earlier intervention” and could complement existing early detection methods.
Dr. Vijay Gunuganti, an oncologist at Texas Oncology, noted that CyPath Lung “can provide additional information without immediately subjecting the patient to an invasive procedure.”
Dr. Gordon Downie, Chief Medical Officer at BioAffinity, emphasized that completing treatment is “not the end of cancer care,” highlighting the increasing significance of post-treatment survivorship monitoring.
Trading Activity and Analyst Outlook
Share volume on Tuesday exceeded 17 million, substantially above the three-month daily average of approximately 5.91 million. Such dramatic volume increases typically indicate rapid retail investor interest in response to news catalysts.
CyPath Lung is classified as a Laboratory Developed Test and has not received clearance as an independent diagnostic device. The clinical efficacy data referenced pertains to early detection applications and has not undergone separate validation for post-treatment monitoring purposes.
Spark’s AI-powered analyst maintains an Underperform rating on BIAF with a $5.50 price target, highlighting concerns about severe cash burn, declining revenue performance, and potential Nasdaq delisting as primary risk factors.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
